Alternate TextTo enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
Home > Products > Novel inhibitors

Novel inhibitors

You can also try the following methods, and our professionals will serve you Customized Consultation
Cat. No. Product Name Field of Application Chemical Structure
DCC2260 Glenvastatin
Novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
More description
DCC2259 glaziovianin A
Novel inhibitor of the cell cycle progression in M-phase; Inhibotor of endosome maturation
More description
DCC2258 Gkm001
First-in-class liver-selective glucokinase activator for the treatment of type 2 diabetes
More description
DCC2257 Gka-71
Novel and potent glucokinase activator (GKA)
More description
DCC2256 Gka-22
Novel Allosteric Activator of Human Glucokinase in the Absence of Glucose
More description
DCC2255 Gk-667
Novel water solubile prodrug of ICRF-193, penetrating into NVCMs, reaching intracellular concentrations sufficient to induce cytoprotective effects against ANT toxicity
More description
DCC2254 Gk-136901
First-in-Class, Potent, and Orally Bioavailable NADPH Oxidase Isoform 4 (Nox4) Inhibitor
More description
DCC2253 Ginnalin A
Natural Activator of the Nrf2-Regulated Antioxidant Defense System in SH-SY5Y Cells, Binding to the Subpockets of Keap1 Kelch Domain
More description
DCC2252 Ginkgonitroside
Natural suppressor of mesenchymal stem cell (MSC) differentiation
More description
DCC2250 Gif-0856-r
Novel suppressor of endoplasmic reticulum (ER) stress and oxidative stress, preventing protein aggregate accumulation in vitro and in cultured hippocampal HT22 neuronal cells, as well as glutamate-induced oxytosis and erastin-induced ferroptosis
More description
DCC2249 Gif-0854-r
Novel suppressor of endoplasmic reticulum (ER) stress and oxidative stress, preventing protein aggregate accumulation in vitro and in cultured hippocampal HT22 neuronal cells, as well as glutamate-induced oxytosis and erastin-induced ferroptosis
More description
DCC2248 Gidazepam
Potent mitochondrial benzodiazepine receptors (MBRs) ligand; Prodrug for its active metabolite bromo-nordazepam
More description
DCC2247 Gic-1001
Novel oral anti-nociceptive agent, showing peripheral opioid agonistic activity and hydrogen sulphide-releasing capacity
More description
DCC2246 Gi261520a
Potent EGFR/erbB2 dual inhibitor
More description
DCC2245 Gi-129471
Metalloproteinase inhibitor, specifically blocking TNF-alpha secretion both in vitro and in vivo
More description
DCC2244 Ghsr Inverse Agonist 29
Novel nonpeptidic inverse agonist of the Ghrelin Receptor (GHSR)
More description
DCC2243 G-glu-glu
Endogenous dipeptide, activating N-methyl-D-aspartate receptors
More description
DCC2241 Geopyxin F
Natural non-covalent NRF2 activator, activating NRF2 in A KEAP1-dependent but Cys151-independent manner, conferring greater protection than a Cys151-dependent analog, geopyxin C
More description
DCC2240 Geopyxin C
Natural covalent Cys151-dependent NRF2 activator
More description
DCC2239 Geneseroline
Metabolite of ganstigmine, a novel acetylcholinesterase inhibitor
More description
DCC2238 Genaconazole
Novel antifungal agent
More description
DCC2237 Geiparvarin
MAO inhibitor
More description
DCC2236 Gebr-7b
Novel Phosphodiesterase 4D (PDE4D) Inhibitor
More description
DCC2235 Gdk-100017
Inhibitor of the Wnt/beta-catenin signaling pathway, suppressing cell proliferation and enhancing radiosensitivity in A549/Wnt2 cells.
More description
DCC2233 Gdc-0917
Novel SMAC mimetic and IAP antagonist
More description
DCC2232 Gdc-0834
Novel Bruton's tyrosine kinase (BTK) inhibitor
More description
DCC2231 Gdc-0575 Dihydrochloride
Novel potent, selective and orally bioavailable Chk1 inhibitor
More description
DCC2230 Gdc0575
Novel highly-selective oral checkpoint kinase 1 (Chk1) inhibitor
More description
DCC2229 Gcs Inhibitor Bz1
Novel glucosylceramide synthase (GCS) inhibitor, rescuing lysosomal deficits, α-synuclein pathology and neuron toxicity
More description
DCC2228 Gcc5694a
Novel Potent and Selective Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
More description

Customized Consultation X

Your information is safe with us. * Required Fields.

Your name
Company
Email
Procuct Name
Cat. No.
Remark
Verification code
Please fill out the characters in the picture
X